Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation

被引:58
作者
Patel, RJ
Witt, DM
Saseen, JJ
Tillman, DJ
Wilkinson, DS
机构
[1] Kaiser Permanente, Dept Clin Pharm, Denver, CO 80205 USA
[2] Kaiser Permanente, Clin Pharm Anticoagulat Serv, Westminster, CO USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Pharm Practice, Denver, CO 80202 USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 10期
关键词
D O I
10.1592/phco.20.15.1159.34585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To compare the efficacy of managing excessive anticoagulation in the absence of bleeding by either omitting warfarin therapy alone or administering oral phytonadione in addition to omitting warfarin therapy. Design. Randomized, double-blind, placebo-controlled study. Setting. Clinical pharmacy anticoagulation service in a group model health maintenance organization. Subjects. Thirty nonbleeding patients with international normalized ratios (INRs) ranging from 6.0-10.0. Interventions. Patients were randomized to receive either a single oral dose of phytonadione 2.5 mg or placebo. Both groups omitted warfarin doses until the INR became less than or equal to 4.0. Measurements and Results. The mean calculated time to reach an INR of 4.0 was significantly greater in the placebo than the phytonadione group (2.6 vs 1.4 days, p=0.006). Overcorrection of anticoagulation was significantly more common in patients receiving phytonadione. Overt warfarin resistance was not observed in either group after reinitiating warfarin therapy. No major bleeding or thromboembolic complications occurred, and minor bleeding episodes were similar in both groups. Conclusion. The addition of oral phytonadione 2.5 mg reduced the time to achieve an INR of 4.0 by approximately 1 day compared with omitting warfarin therapy alone. Adverse events did not differ between the two groups. Both strategies were effective in managing asymptomatic patients with INRs of 6.0-10.0. Oral phytonadione may be most appropriate for patients at high risk for bleeding in whom the benefit of prompt INR reduction would outweigh the thromboembolic risk associated with INR overcorrection.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 14 条
  • [1] OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES
    CANNEGIETER, SC
    ROSENDAAL, FR
    WINTZEN, AR
    VANDERMEER, FJM
    VANDENBROUCKE, JP
    BRIET, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) : 11 - 17
  • [2] Crowther MA, 1998, THROMB HAEMOSTASIS, V79, P1116
  • [3] Duong TM, 1998, PHARMACOTHERAPY, V18, P1264
  • [4] DZUNG TL, 1994, ANN INTERN MED, V120, P552
  • [5] CONSERVATIVE TREATMENT OF OVERANTICOAGULATED PATIENTS
    GLOVER, JJ
    MORRILL, GB
    [J]. CHEST, 1995, 108 (04) : 987 - 990
  • [6] Mechanism of action, clinical effectiveness, and optimal therapeutic range
    Hirsh, J
    Dalen, JE
    Anderson, DR
    Poller, L
    Bussey, H
    Ansell, J
    Deykin, D
    Brandt, JT
    [J]. CHEST, 1998, 114 (05) : 445S - 469S
  • [7] Management of anticoagulation before and after elective surgery
    Kearon, C
    Hirsh, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (21) : 1506 - 1511
  • [8] Evaluation of excessive anticoagulation in a group model health maintenance organization
    Lousberg, TR
    Witt, DM
    Beall, DG
    Carter, BL
    Malone, DC
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (05) : 528 - 534
  • [9] COMPARISON OF THROMBOPLASTINS USING THE ISI AND INR SYSTEM
    MORIARTY, HT
    LAMPOTANG, PRL
    ANASTAS, N
    [J]. PATHOLOGY, 1990, 22 (02) : 71 - 76
  • [10] ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236